Opiant Pharmaceuticals, Inc. (OPNT): Price and Financial Metrics


Opiant Pharmaceuticals, Inc. (OPNT)

Today's Latest Price: $9.33 USD

0.17 (1.86%)

Updated Jan 22 4:00pm

Add OPNT to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

OPNT Stock Summary

  • With a market capitalization of $39,728,120, Opiant Pharmaceuticals Inc has a greater market value than only 8.77% of US stocks.
  • For OPNT, its debt to operating expenses ratio is greater than that reported by merely 5.15% of US equities we're observing.
  • With a year-over-year growth in debt of -52.93%, Opiant Pharmaceuticals Inc's debt growth rate surpasses merely 5.7% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Opiant Pharmaceuticals Inc are SDGR, IDN, PING, CSBR, and RDFN.
  • Visit OPNT's SEC page to see the company's official filings. To visit the company's web site, go to www.opiant.com.

OPNT Stock Price Chart Interactive Chart >

Price chart for OPNT

OPNT Price/Volume Stats

Current price $9.33 52-week high $13.70
Prev. close $9.16 52-week low $6.79
Day low $9.21 Volume 34,000
Day high $9.46 Avg. volume 40,093
50-day MA $8.35 Dividend yield N/A
200-day MA $9.00 Market Cap 39.73M

Opiant Pharmaceuticals, Inc. (OPNT) Company Bio


Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops opioid antagonist treatments for addictions and related disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. It is also involved in developing treatments for binge eating disorder and cocaine use disorder, as well as Bulimia Nervosa, an eating disorder; and heroin vaccine. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is based in Santa Monica, California. Opiant Pharmaceuticals, Inc. operates as a subsidiary of Pelikin Group.


OPNT Latest News Stream


Event/Time News Detail
Loading, please wait...

OPNT Latest Social Stream


Loading social stream, please wait...

View Full OPNT Social Stream

Latest OPNT News From Around the Web

Below are the latest news stories about Opiant Pharmaceuticals Inc that investors may wish to consider to help them evaluate OPNT as an investment opportunity.

The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 14) * Acceleron Pharma Inc (NASDAQ: XLRN) (announced orphan drug designation for sotatercept in pulmonary arterial hypertension) * Adaptive Biotechnologies Corp (NASDAQ: ADPT) * Affimed NV (NASDAQ: AFMD) * Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) - announced a deal to be bought by AstraZeneca plc (NASDAQ: AZN) for $39 billion * Agios Pharmaceuticals Inc (NASDAQ: AGIO) * Alkermes Plc (NASDAQ: ALKS) * Amicus Therapeutics, Inc. (NASDAQ: FOLD) * Apellis Pharmaceuticals Inc (NASDAQ: APLS) * argenx SE - ADR (NASDAQ: ARGX) * Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) * Arvinas Inc (NASDAQ: ARVN) (announced positive results for early st...

Yahoo | December 15, 2020

Opiant Pharmaceuticals Announces Additional $3.5 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program

SANTA MONICA, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced an additional commitment of up to $3.5 million from the Biomedical Advanced Research and Development Authority (“BARDA”), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to advance the clinical development of OPNT003, nasal nalmefene, for opioid overdose. The contract modification increases the total potential value of the BARDA contract to $8.1 million. “We thank BARDA for their ongoing support of OPNT003, nasal nalmefene,” said Roger Crystal, M.D., President and Chief Executive Officer of Opiant. “We believe OPNT003, nasal nalmefene, has the potential to be a best-in-class rescue...

Yahoo | December 14, 2020

Opiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing

SANTA MONICA, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today that it has entered into a $50 million convertible Note Purchase and Security Agreement (“Agreement”) with a syndicate of Pontifax Medison Finance (“Pontifax”), a healthcare-dedicated venture and debt fund, and Kreos Capital, Europe’s leading growth debt firm. Opiant plans to use the proceeds to fund the potential future commercialization of OPNT003, nasal nalmefene, an investigational treatment for opioid overdose, which the company aims to file for approval by the U.S. Food and Drug Administration (“FDA”) at the end of 2021.Under the Agreement, Opiant will be able ...

Yahoo | December 10, 2020

Where Do Hedge Funds Stand On Opiant Pharmaceuticals, Inc. (OPNT)?

In this article we will check out the progression of hedge fund sentiment towards Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and […]

Yahoo | November 27, 2020

Opiant Pharmaceuticals: Q3 Earnings Insights

Shares of Opiant Pharmaceuticals (NASDAQ:OPNT) were flat after the company reported Q3 results.Quarterly Results Earnings per share fell 92.39% over the past year to $0.15, which beat the estimate of ($0.21).Revenue of $9,106,000 decreased by 55.88% from the same period last year, which beat the estimate of $7,760,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.Opiant Pharmaceuticals hasn't issued any revenue guidance for the time being.Details Of The Call Date: Nov 12, 2020View more earnings on OPNTTime: 04:30 PMET Webcast URL: http://ir.opiant.com/Technicals Company's 52-week high was at $18.23Company's 52-week low was at $6.79Price action over last quarter: down 20.57%Company Description Opiant Pharmaceuticals Inc is a specialty pharmaceutical company op...

Yahoo | November 12, 2020

Read More 'OPNT' Stories Here

OPNT Price Returns

1-mo 13.09%
3-mo 25.79%
6-mo 1.97%
1-year -26.82%
3-year -55.27%
5-year -1.79%
YTD 16.19%
2020 -44.24%
2019 -0.35%
2018 -37.09%
2017 309.45%
2016 -43.05%

Continue Researching OPNT

Here are a few links from around the web to help you further your research on Opiant Pharmaceuticals Inc's stock as an investment opportunity:

Opiant Pharmaceuticals Inc (OPNT) Stock Price | Nasdaq
Opiant Pharmaceuticals Inc (OPNT) Stock Quote, History and News - Yahoo Finance
Opiant Pharmaceuticals Inc (OPNT) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8516 seconds.